Suchen
AIM ImmunoTech Inc
AIMZur Watchlist hinzufügen
0.279USD
-0.017-5.84%
Handelsschluss 06/30, 16:00（ET）Kurse um 15 Minuten verzögert
2.29MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über AIM ImmunoTech Inc Unternehmen
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc Informationen
BörsenkürzelAIM
Name des UnternehmensAIM ImmunoTech Inc
IPO-datumJul 12, 1996
CEOEquels (Thomas K)
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJul 12
Addresse2117 Sw Highway 484
StadtOCALA
BörseNASDAQ OMX – NASDAQ Basic Amex
LandUnited States of America
Postleitzahl32801
Telefon13524487797
Websitehttps://aimimmuno.com/
BörsenkürzelAIM
IPO-datumJul 12, 1996
CEOEquels (Thomas K)
Führungskräfte von AIM ImmunoTech Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von AIM ImmunoTech Inc?
Die fünf größten Anteilseigner von AIM ImmunoTech Inc sind: Mr. Thomas K. Equels, Esq., J.D.
Wie viele Institutionen halten Anteile an AIM ImmunoTech Inc (AIM)?
Mit Stand vom 2026Q1 halten 57 Institutionen Anteile an AIM ImmunoTech Inc, mit einem Gesamtmarktwert von etwa 105.74K, was 1.30% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -74291.00 gestiegen.
